Literature DB >> 21606639

Two atypical cases of cutaneous gamma/delta T-cell lymphomas.

A Caudron1, J D Bouaziz, M Battistella, D Sibon, C Lok, C Leclech, N Ortonne, V Molinier-Frenkel, M Bagot.   

Abstract

Cutaneous γ/δ T-cell lymphoma (CGD-TCL) is a recent entity described in the newly revised World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas, and is characterized by the γ/δ T-cell receptor expression on atypical lymphocytes. Only a few cases of primary CGD-TCL have been reported, with an extremely aggressive course (median survival time of 15 months). We describe 2 atypical cases of CGD-TCL. The first case was initially misdiagnosed as an inflammatory panniculitis due to the granulomatous infiltrate on the skin biopsy specimen. Diagnosis was confirmed using δ PCR that revealed γ/δ T-cell clonal expansion. The evolution was marked by predominant γ/δ T-cell infiltrate with diffuse body fat involvement as seen on positron emission tomography-computed tomography. The second case is the first described Epstein-Barr virus (EBV)-associated CGD-TCL with a rapidly fatal evolution. CGD-TCL is also a heterogeneous entity and δ PCR and EBV-encoded RNA probe to detect an EBV latent infection may help diagnose and characterize these cutaneous lymphomas.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606639     DOI: 10.1159/000327932

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  2 in total

1.  Primary cutaneous γ/δ T-cell lymphoma. An atypical case with bone marrow granulomas.

Authors:  Guy Shalom; Ronit Gurion; Daniel Benharroch
Journal:  J Dermatol Case Rep       Date:  2015-03-31

2.  Analysis of differential β variable region of T cell receptor expression and NAV3/TNFRSF1B gene mutation in mycosis fungoides.

Authors:  Hongzhou Cui; Jie Liu; Li Li; Jingyu Ren; Shuping Guo; Li Bai
Journal:  Oncotarget       Date:  2016-04-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.